The congress of European Society of Toxicology In Vitro (ESTIV) took place from 21st to 25th November 2022. This congress is focus on the alternative methods to animal testing, including both in silico and in vitro modeling. After a nice opening ceremony with a flamenco show, the scientific program begun Read more…
We are pleased to participate to the 21st International Congress of the European Society of Toxicology In Vitro (ESTIV 2022), which will take place in Barcelona-Sitges, Spain, from 21st to 25th November 2022. Our project Leader in in vitro pharmacology Véronique De Conto will present her poster entitled “In vitro microenvironment modifies the neurotoxic Read more…
Présentation en français About 90% of drug-candidates failed in clinical trials, in particular in neurology, due to a lack of efficacy. That highlights a lack of relevance in preclinical models, including in vitro models, which do not take into account the microenvironment, composed by glial cells and the Extracellular Matrix Read more…
It is our pleasure to announce that the article of our PhD Student Véronique De Conto has been published in Toxicology in vitro journal. This work comes from a collaboration between HCS Pharma and Inserm Unit “Degenerative & vascular cognitive disorders”. This article highlight the importance to consider carefully the Read more…
We were glad to welcome Roberta Bilardo for a 2 month-secondment in HCS Pharma in the frame of Nanostem project (Developing NANOmaterials for neural STEM cells drug delivery). She is working as a Marie Curie Fellow Early Stage Researcher in Prof Resmini’s research group at the School of Biological and Read more…
Since last year, our PhD student Véronique De Conto has been working on the impact of microenvironment in cerebral in vitro model. On the supervision of our study director Dr. Elodie Vandenhaute and her thesis director Pr. Vincent Bérézowski (Inserm U1171), she developed two different cerebral in vitro models: A Read more…
The first version of BIOMIMESYS Brain allows to form neurospheres. We now developped a new version of BIOMIMESYS Brain, which allows to form neuronal networks. This version have a higher porosity than BIOMIMESYS Brain (Neurosphere), that allows to better disperse the cells and thus to form cell network instead of Read more…
A new BIOMIMESYS® hydroscaffold is available for 3D cell culture! This hydroscaffold is suitable for neuronal cell culture. We tested it for two cell lines: SH-SY5Y cells, commonly used for pharmaceutical research, and LUHMES cells (dopaminergic neurons). Cells grow and form spheroids with intra and inter-spheroidal neurites. BIOMIMESYS® hydroscaffold allows Read more…
Our study director Elodie will attend Drug Discovery 2018 – THE ELRIG‘s flagship conference – which will take place in London next week! We are looking forward to presenting our poster about neurotoxicity testing. Don’t hesitate to visit Elodie there, she will answer to your questions about our results, and/or our different services! Read more…
Ask for high quality link by entering your email below As shown by AstraZeneca in Nature reviews*, one third of the safety failures is linked to CNS toxicity during the clinical trials of drugs. Therefore, relevant in vitro human models are needed to detect early neurotoxicity of drug candidates. In Read more…
Next week (the 23th and the 24th of May), we will be in Strasbourg to participate to ELRIGfr event, where we will present two posters. The first poster is about BIOMIMESYS® hydroscaffold for 3D cell culture and the compatibility with automation; the plates can be seeded, treated easily using the VIAFLO 96/384. Read more…
One third of the safety failures is linked to CNS toxicity during the clinical trials of drugs. In order to develop a more predictable in vitro human model for neurotoxicity testing, we have compared the sensibility of iPSC-derived neuronal cells and SH-SY5Y cell line (neuroblastoma-derived cell line) to a panel Read more…
Last friday (10/11), we presented our neurotoxicity and genotoxicity assays at the French Agency for Food and Safety (ANSES)
Ask for a high quality version of this poster : As shown by AstraZeneca in nature reviews*, one third of safety failures along the drug discovery process is linked to CNS toxicity uncovered in clinical trials. To avoid this attrition, the potential neurotoxicity of any drug going through the blood brain barrier Read more…
We were in Saint Malo for the first meeting on DYRKs related disease
As shown by AstraZeneca in nature reviews, one third of the safety failures is linked to CNS toxicity during the clinical trials of drugs .